AbstractPrevious studies have shown that the breast cancer suppressor BRCA1 stimulates antioxidant gene expression and protects cells against oxidative stress. To further examine this important function, we tested whether BRCA1 could modulate intracellular levels of reactive oxygen species (ROS). Wild-type BRCA1 (but not a cancer-associated mutant) significantly reduced ROS levels, determined by DCF fluorescence assays by flow cytometry and confocal microscopy. The BRCA1 and REF1 pathways for reduction of ROS levels appear to exhibit cross-talk. BRCA1 also reduced the levels of protein nitration and H2O2-induced oxidative damage to DNA. Thus, BRCA1 may protect cellular macromolecules by reducing intracellular ROS levels
The hereditary breast and ovarian tumor suppressor BRCA1 can activate p53-dependent gene expression....
Inherited mutations in the BRCA1 gene predispose to a higher risk of breast/ovarian cancer. The BRCA...
Germline mutations to BRCA1 account for approximately 30% of familial breast cancer, with carriers h...
The breast cancer susceptibility gene 1 (BRCA1) has been well established as a tumor suppressor and ...
The BRCA1 (Breast Cancer 1, early onset) tumor suppressor gene is the most frequently mutated gene i...
BackgroundExcessive production of reactive oxygen species (ROS), in part via upregulation of DNA dam...
There remains great interest in practical strategies to limit the elevated risks of familial breast ...
Mutations in the BRCA1 tumor suppressor gene are commonly found in hereditary breast cancer. Similar...
Oxidative stress plays an important role in cancer development and treatment. Recent data implicate ...
International audienceThe hypermetabolic nature of cancer cells and their increased reliance on ''ae...
The hypermetabolic nature of cancer cells and their increased reliance on "aerobic glycolysis", as o...
The hypermetabolic nature of cancer cells and their increased reliance on "aerobic glycolysis'', as ...
Copyright © 2013 Daniele Fanale et al. This is an open access article distributed under the Creative...
BRCA1 (breast-cancer susceptibility gene 1) is a tumour suppressor, implicated in the hereditary pre...
The evolving history of BRCA1 research demonstrates the profound interconnectedness of a single prot...
The hereditary breast and ovarian tumor suppressor BRCA1 can activate p53-dependent gene expression....
Inherited mutations in the BRCA1 gene predispose to a higher risk of breast/ovarian cancer. The BRCA...
Germline mutations to BRCA1 account for approximately 30% of familial breast cancer, with carriers h...
The breast cancer susceptibility gene 1 (BRCA1) has been well established as a tumor suppressor and ...
The BRCA1 (Breast Cancer 1, early onset) tumor suppressor gene is the most frequently mutated gene i...
BackgroundExcessive production of reactive oxygen species (ROS), in part via upregulation of DNA dam...
There remains great interest in practical strategies to limit the elevated risks of familial breast ...
Mutations in the BRCA1 tumor suppressor gene are commonly found in hereditary breast cancer. Similar...
Oxidative stress plays an important role in cancer development and treatment. Recent data implicate ...
International audienceThe hypermetabolic nature of cancer cells and their increased reliance on ''ae...
The hypermetabolic nature of cancer cells and their increased reliance on "aerobic glycolysis", as o...
The hypermetabolic nature of cancer cells and their increased reliance on "aerobic glycolysis'', as ...
Copyright © 2013 Daniele Fanale et al. This is an open access article distributed under the Creative...
BRCA1 (breast-cancer susceptibility gene 1) is a tumour suppressor, implicated in the hereditary pre...
The evolving history of BRCA1 research demonstrates the profound interconnectedness of a single prot...
The hereditary breast and ovarian tumor suppressor BRCA1 can activate p53-dependent gene expression....
Inherited mutations in the BRCA1 gene predispose to a higher risk of breast/ovarian cancer. The BRCA...
Germline mutations to BRCA1 account for approximately 30% of familial breast cancer, with carriers h...